Conditions

Home / Conditions

 

Unusual Case Cites Infection as Possible Trigger of Sarcoidosis

Unusual Case Cites Infection as Possible Trigger of Sarcoidosis

This post was originally published on this site A study reporting the case of a sarcoidosis patient infected with the bacteria Borrelia burgdorferi highlights the importance of maintaining an increased awareness about potential infectious conditions, such as Lyme disease, in patients with new onset of sarcoidosis. The case study, “Systemic Sarcoidosis Associated with Exposure to Borrelia burgdorferi…

NantKwest, ProMab Partner to Develop Natural Killer Cell Therapy for Multiple Myeloma, Other Blood Cancers

NantKwest, ProMab Partner to Develop Natural Killer Cell Therapy for Multiple Myeloma, Other Blood Cancers

This post was originally published on this site NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation antigen, or BCMA. The therapy, called chimeric antigen receptor (CAR) NK-cell, is a tweaked version of the conventional CAR-T cell therapy: instead of isolating…

GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC

GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC

This post was originally published on this site Adding Celsion‘s GEN-1 to standard chemotherapy — given prior to surgery — stops disease progression in patients with newly diagnosed advanced ovarian cancer and helps remove the tumor successfully during surgery, without causing significant side effects, a Phase 1b trial shows. The trial’s data were presented at the…

Some PC Patients Can Safely Receive Short but Intense Course of Radiation

Some PC Patients Can Safely Receive Short but Intense Course of Radiation

This post was originally published on this site Stereotactic body radiotherapy (SBRT), which delivers higher doses of radiation over a significantly shorter period of time, can be safely given to men with low- or intermediate-risk prostate cancer with similar long-term efficacy as conventional radiation therapy, a study shows. The approach, which reduces the duration of treatment…

Dosing Starts in Phase 2 trial of Bryostatin-1 for Alzheimer’s

Dosing Starts in Phase 2 trial of Bryostatin-1 for Alzheimer’s

This post was originally published on this site Neurotrope Bioscience announced that dosing of patients has started in its Phase 2 clinical trial to further evaluate Bryostatin-1, the company’s investigational candidate for the treatment of moderate to severe Alzheimer’s disease. “Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding…

Reaching the Double Nickel

Reaching the Double Nickel

This post was originally published on this site I shivered in the parking lot at my kid’s school with four other moms. Originally, I planned to peel out of there before anyone could see me, but Leeanne caught my eye and then I saw Shannon, and before I knew it, I was parking the car…

Alligator Bioscience Starts Phase 1 Trial to Test ATOR-1015 in Advanced Solid Tumors

Alligator Bioscience Starts Phase 1 Trial to Test ATOR-1015 in Advanced Solid Tumors

This post was originally published on this site The first patient has been dosed in Alligator Bioscience’s Phase 1 clinical trial testing the investigational immunotherapy ATOR-1015 as a new treatment for advanced solid tumors, the company announced. The open-label trial (NCT03782467) will assess the safety, tolerability, and early efficacy of ATOR-1015 in approximately 53 adults who failed…

CTCL Patients Who Continue Treatment Use Fewer Hospital Resources, Study Says

CTCL Patients Who Continue Treatment Use Fewer Hospital Resources, Study Says

This post was originally published on this site Patients with cutaneous T-cell lymphoma (CTCL) who for some reason discontinue their systemic treatments require more monthly emergency room visits, hospital admissions, and longer inpatient stays than those who continue on treatment, a study by the pharmaceutical company Mallinckrodt found. Researchers estimate that, each month, those who…

Combination of 2 Dietary Compounds May Have Benefits for Alzheimer’s Patients, Mouse Study Suggests

Combination of 2 Dietary Compounds May Have Benefits for Alzheimer’s Patients, Mouse Study Suggests

This post was originally published on this site Combining two dietary compounds found in green tea and carrots reversed cognitive deficits, lowered the accumulation of toxic amyloid beta, and reduced brain inflammation and oxidative damage in a mouse model of Alzheimer’s disease, a study reports. The study, “Combined treatment with the phenolics (−)-epigallocatechin-3-gallate and ferulic acid…

CHMP Favors EU Approval of Lynparza for Some Advanced Breast Cancers

CHMP Favors EU Approval of Lynparza for Some Advanced Breast Cancers

This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Lynparza (olaparib) tablets for the treatment of advanced breast cancer patients whose tumor is HER2-negative and positive for BRCA mutations. The recommendation is for patients already…

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

This post was originally published on this site The European Commission has approved a combination of Keytruda (pembrolizumab) plus standard chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) announced. The approval — which makes the combination available in all 28 member…

Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma

Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma

This post was originally published on this site Janssen has is seeking approval from the U.S. Food and Drug Administration (FDA) for Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — as a treatment for newly diagnosed multiple myeloma patients ineligible for a stem cell transplant. Janssen’s supplemental Biologics License Application (sBLA) is based on data from the…